Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Benefits and harms of antipsychotic drugs in drug-naïve patients with psychosis: A systematic review

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Presentation of benefits and harms of antidepressants on websites: A cross-sectional study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Long-term harms from previous use of selective serotonin reuptake inhibitors: A systematic review

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Impaired reproduction after exposure to ADHD drugs: Systematic review of animal studies

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Do protocols for new randomised trials take previous similar trials into account? Cohort study of contemporary trial protocols

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. General health checks in adults for reducing morbidity and mortality from disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Increased incidence of cervical cancer in Sweden: an unlikely link with human papillomavirus (HPV) vaccination

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  4. Long-term harms from previous use of selective serotonin reuptake inhibitors: A systematic review

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

OBJECTIVE: To study the benefits and harms of antipsychotics in drug-naïve patients with psychosis.

METHODS: This study is a systematic review and meta-analysis of placebo-controlled trials.

MAIN OUTCOME MEASURES: Mortality, activities of daily living, quality of life, core psychiatric events, and relapse and recovery rates.

DATA SOURCES: PubMed, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), two trial registers and references in potentially eligible articles.

DATA EXTRACTION: Two researchers extracted data independently. The outcomes were planned to be meta-analysed using Review Manager based on a fixed effect model.

RESULTS: Our searches resulted in 493 unique records of which 447 were clearly not eligible. We read the full text of the 46 potentially eligible articles and found one eligible trial in drug-naïve patients, which was unreliable. It was a Chinese trial comparing olanzapine with placebo in 261 patients with first-episode schizophrenia. After 12 weeks, there was an extremely large difference favouring placebo, but the authors reported the opposite, that olanzapine was effective.

CONCLUSIONS: The use of antipsychotics cannot be justified based on the evidence we currently have. Withdrawal effects in the placebo groups make existing placebo-controlled trials unreliable.

OriginalsprogEngelsk
TidsskriftInternational Journal of Risk and Safety in Medicine
Vol/bind30
Udgave nummer4
Sider (fra-til)193-201
Antal sider9
ISSN0924-6479
DOI
StatusUdgivet - 2019

ID: 58919967